S
Steven Salloway
Researcher at Brown University
Publications - 5
Citations - 5855
Steven Salloway is an academic researcher from Brown University. The author has contributed to research in topics: Dementia & Population. The author has an hindex of 5, co-authored 5 publications receiving 5411 citations.
Papers
More filters
Journal ArticleDOI
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Bruno Dubois,Howard Feldman,Claudia Jacova,Steven T. DeKosky,Pascale Barberger-Gateau,Jeffrey L. Cummings,André Delacourte,Douglas Galasko,Serge Gauthier,Gregory A. Jicha,Kenichi Meguro,John T. O'Brien,Florence Pasquier,Philippe Robert,Martin N. Rossor,Steven Salloway,Yaakov Stern,Pieter Jelle Visser,Philip Scheltens +18 more
TL;DR: The NINCDS-ADRDA and DSM-IV-TR criteria for Alzheimer's disease (AD) are the prevailing diagnostic standards in research; however, they have now fallen behind the unprecedented growth of scientific knowledge as discussed by the authors.
Journal ArticleDOI
Revising the definition of Alzheimer's disease: a new lexicon.
Bruno Dubois,Howard Feldman,Howard Feldman,Howard Feldman,Claudia Jacova,Jeffrey L. Cummings,Steven T. DeKosky,Pascale Barberger-Gateau,André Delacourte,Giovanni B. Frisoni,Nick C. Fox,Douglas Galasko,Serge Gauthier,Harald Hampel,Gregory A. Jicha,Kenichi Meguro,John T. O'Brien,Florence Pasquier,Philippe Robert,Martin N. Rossor,Steven Salloway,Marie Sarazin,Leonardo Cruz de Souza,Yaakov Stern,Pieter Jelle Visser,Pieter Jelle Visser,Philip Scheltens +26 more
TL;DR: This paper aims to advance the scientific discussion by providing broader diagnostic coverage of the AD clinical spectrum and by proposing a common lexicon as a point of reference for the clinical and research communities.
Journal ArticleDOI
Aducanumab: Appropriate Use Recommendations
Jeffrey L. Cummings,Paul S. Aisen,Liana G. Apostolova,Alireza Atri,Alireza Atri,Steven Salloway,M. Weiner +6 more
TL;DR: Aducanumab is an amyloid-targeting monoclonal antibody delivered by monthly intravenous infusions for treatment of Alzheimer's disease (AD).
Journal ArticleDOI
Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
TL;DR: This study shows that long-term treatment with donepezil 23 mg/day is associated with no new safety signals and the incidence of new AEs declined rapidly after the first 2 weeks and remained low throughout the duration of the study.
Journal Article
Erratum to "Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial" [Rev. Neurol. 169 (10) (2013) 737-743] (DOI:10.1016/j.neurol.2013.07.017)
SM Mills,J. Mallmann,Anna Santacruz,A. Fuqua,M. Carril,Paul S. Aisen,M. C. Althage,S. Belyew,Tammie L.S. Benzinger,William S. Brooks,Virginia Buckles,Nigel J. Cairns,David B. Clifford,A Danek,Anne M. Fagan,Martin R. Farlow,Nick C. Fox,Bernardino Ghetti,A. Goate,D. Heinrichs,Russ C. Hornbeck,Clifford R. Jack,Mathias Jucker,William E. Klunk,Daniel S. Marcus,Ralph N. Martins,CM Masters,Richard Mayeux,Eric McDade,John C. Morris,Angela Oliver,John M. Ringman,Martin N. Rossor,Steven Salloway,Peter R. Schofield,J Snider,Peter J. Snyder,Reisa A. Sperling,C Stewart,Rhodri Thomas,Chengjie Xiong,Randall J. Bateman +41 more